Antiparkinson Agents (Antiparkinsonian Agents)

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Also Known As:

Networked: 129 relevant articles (9 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Stuart, Bruce: 3 articles (03/2014 - 08/2010)
2.	Millan, Mark J: 3 articles (02/2011 - 11/2002)
3.	Ohyagi, Yasumasa: 2 articles (12/2020 - 02/2002)
4.	Beardsley, Robert: 2 articles (03/2014 - 10/2013)
5.	Palumbo, Francis B: 2 articles (03/2014 - 10/2013)
6.	Shulman, Lisa M: 2 articles (03/2014 - 10/2013)
7.	Simoni-Wastila, Linda: 2 articles (03/2014 - 10/2013)
8.	Wei, Yu-Jung: 2 articles (03/2014 - 10/2013)
9.	Aloisi, Gabriella: 2 articles (02/2011 - 12/2009)
10.	Maggio, Roberto: 2 articles (02/2011 - 12/2009)

Related Diseases

1.	Dyskinesias (Dyskinesia) 01/01/1992 - "Longer exposure to antiparkinson drugs was associated with delayed onset of dyskinesia. " 01/01/2000 - "In logistic-regression analysis, the overall model attained significance in predicting functional impairment, and three predictor variables-abnormal movements, use of antiparkinsonian agents, and negative symptoms-attained independent significance. " 06/14/1986 - "The problems of long term treatment with antiparkinson drugs are numerous, involving increased involuntary movements, painful dystonic cramps, decrease or loss of therapeutic benefit, wearing-off, episodes of akinesia (on-off) and long periods of "freezing". " 05/01/2006 - "Physicians have been concerned about forestalling the appearance of dyskinesias and motor fluctuations, whereas patients have incorrectly understood that L-dopa and possibly other antiparkinson drugs have a finite duration of usefulness, making it important to defer treatment for as long as possible. " 01/01/2003 - "In addition, MPTP-treated primates are responsive to all commonly used antiparkinsonian agents and display treatment-associated motor complications such as dyskinesia, wearing-off and on-off, which occur during the long-term treatment of the illness. "
2.	Parkinson Disease (Parkinson's Disease) 08/01/2015 - "[Treatments for Parkinson's Disease -Essential Knowledge for General Physicians - Topics: III. Recommended Usage of New Antiparkinson Drugs]." 03/01/2014 - "We examine the associations of adherence to antiparkinson drugs (APDs) with health care utilization and economic outcomes among patients with Parkinson's disease (PD). " 10/01/2013 - "Antiparkinson drugs (APDs) are the mainstay of managing Parkinson's disease (PD). " 08/01/2010 - "Antiparkinson drugs (APDs) are the mainstay in the management of Parkinson's disease (PD). " 12/01/2006 - "To analyze the dispensation of antiparkinsonian agents in Spain and to estimate the Parkinson's disease prevalence. "
3.	Dystonia (Limb Dystonia) 10/01/1987 - "If confirmed, these data may allow treatment strategies that protect patients from dystonia while sparing patients not at risk unnecessary treatment with antiparkinson agents." 01/01/1988 - "Neuropharmacological studies performed in 12 patients suggest that off-period dystonia is genuinely induced by L-dopa and best relieved by antiparkinsonian agents." 09/01/1987 - "Recent research suggests efficacy of prophylactic antiparkinson drugs in diminishing the incidence of acute dystonia in high-risk patients, although the use of lower neuroleptic doses also might lower the risk and cause fewer unwanted effects. "
4.	Tremor (Tremors) 09/01/1987 - "The tremors could not be controlled with antiparkinsonian agents. " 01/01/1973 - "[Epidemic tremor in chickens as a model for the testing of antiparkinson drugs]." 07/01/1995 - "MPTP-treated common marmosets showed tremor and akinesia, and it remarkably responded to antiparkinsonian agents. " 05/01/2000 - "However, studies comparing pramipexole with other antiparkinsonian agents would be useful to further define its benefits in the treatment of tremor-dominant Parkinson's disease and to further document its favourable adverse event profile." 01/01/1978 - "This is the converse of the experience gained with the classical antiparkinson agents, which have proved more effective against tremor induced by neuroleptics than against lithium-induced tremor."
5.	Parkinsonian Disorders (Parkinsonism) 12/01/2020 - "Five months after onset, the patient was free from parkinsonism without the use of any antiparkinsonian agents. " 01/01/1983 - "Antiparkinson drugs alleviate major symptoms like akinesia and rigidity but sometimes and especially as reflection of advanced parkinsonism, might amplify minor symptoms (freezing, off-phases, Yo-Yoing), which then predominantly at high drug doses occur earlier and more intensively. " 07/01/1954 - "Parkinsonism: preliminary report on two new antiparkinsonian agents." 02/25/1949 - "Treatment of parkinsonian syndromes by synthetic antiparkinsonians; first North African results." 07/01/2023 - "A Case of Organophosphate Poisoning Inducing Parkinsonism which was Effectively Treated by Antiparkinson Drugs."

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Levodopa (L Dopa)
3.	Haloperidol (Haldol)
4.	Therapeutic Uses
5.	Muscarinic Antagonists
6.	Lithium
7.	Tiapride Hydrochloride
8.	dironyl (terguride)
9.	Benzodiazepines
10.	Antidepressive Agents (Antidepressants)

Related Therapies and Procedures

1.	Therapeutics
2.	Polypharmacy
3.	Deep Brain Stimulation
4.	Home Nursing (Nursing, Home)
5.	Contraindications